Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Wyeth Research Division of Wyeth Pharmaceuticals Inc
Woman and Man Max 99 years
Global Medical Affairs, Wyeth Research Division of Wyeth Pharmaceuticals Inc
Update Il y a 4 ans
A Randomised, Double-Blind, Two-Period Study to Evaluate the Safety and Efficacy of Etanercept on Skin and Joint Disease in Psoriasis Subjects with Psoriatic Arthritis
To compare the efficacy of two different treatment regimens of etanercept in treating the skin manifestations of psoriasis subjects with PsA over 12 weeks. The study hypothesis is that etanercept 50 ...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Wyeth Research Division of Wyeth Pharmaceuticals Inc
Update Il y a 4 ans
A phase 3, randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healhy Infants Given With Routine Pediatric Vaccination in Italy
Primary objective To demonstrate that the immune response induced by Infanrix hexa given with 13vPnC is noninferior to the immune response induced by Infanrix hexa given with 7vPnC when measured 1 ...
Country
None
organs
None
Specialty
None
Closed trial
More information
Man Max 99 years
Wyeth Research Division of Wyeth Pharmaceuticals Inc
Update Il y a 4 ans
An Open-Label Study to Evaluate Prophylaxis Treatment, and to Characterize the , Efficacy, Safety and Pharmacokinetics of B Domain Deleted Recombinant Factor VIII Albumin Free (ReFacto AF) in Children With Hemophilia A Estudio abierto para evaluar el tratamiento profiláctico y para caracterizar la eficacia, la seguridad y la farmacocinética del factor VIII recombinante con delección del dominio B sin albúmina (ReFacto® AF) en niños con hemofilia A
To demonstrate that ReFacto AF prophylaxis reduces annualized bleeding rates (ABRs) relative to on-demand therapy.
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Wyeth Research Division of Wyeth Pharmaceuticals Inc, Clinical Research and Development
Update Il y a 4 ans
A MULTICENTER, RANDOMIZED, OPEN LABEL, SINGLE AND MULTIPLE DOSE STUDY OF THE PHARMACOKINETICS AND PHARMACODYNAMICS OF 2 DOSE LEVELS OF PANTOPRAZOLE SODIUM ENTERIC-COATED SPHEROID SUSPENSION IN INFANTS AGED 1 THROUGH 11 MONTHS WITH PRESUMED GERD
To characterize the PK profile of single and repeated doses of pantoprazole and the PD profile at baseline and at steady state after multiple doses of pantoprazole in infants aged 1 through 11 months ...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman Max 99 years
Wyeth Research Division of Wyeth Pharmaceuticals Inc
Update Il y a 4 ans
Estudio de fase 2, aleatorizado y abierto, de bosutinib administrado en combinación con exemestano frente a exemestano solo como tratamiento de segunda línea en mujeres posmenopáusicas con cáncer de mama RE+/RPg+/ErbB2- localmente avanzado o metastático
The primary objective is to compare efficacy, as measured by PFS and assessed by an independent radiology read, of bosutinib in combination with exemestane with that of exemestane alone.
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Wyeth Research Division of Wyeth Pharmaceuticals Inc
Update Il y a 4 ans
A phase 1/2, open-label study of bosutinib administered in combination with capecitabine in subjects with solid tumor and ErbB2 negative locally advanced or metastatic breast cancer
For part 1, the primary objective is to assess the safety and tolerability, and to determine the MTD(s) of bosutinib plus capecitabine in patients with locally advanced or metastatic breast cancer or ...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Wyeth Research Division of Wyeth Pharmaceuticals Inc
Update Il y a 4 ans
A Randomized, Double-blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of Subcutaneous Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Subjects With Cancer-Related Pain Estudio aleatorizado, en doble ciego y controlado con placebo, para evaluar la seguridad y la eficacia de la metilnaltrexona subcutánea en el tratamiento del estreñimiento inducido por opiáceos en pacientes con dolor de origen tumoral
The objective of this study is to evaluate the efficacy and safety of sub-cutaneous methylnaltrexone in relieving opioid-induced constipation in subjects with cancer-related pain.
Country
None
organs
None
Specialty
None
unknown
More information
Woman Max 99 years
Wyeth Research Division of Wyeth Pharmaceuticals Inc
Update Il y a 4 ans
FRACTURE INCIDENCE REDUCTION AND SAFETY OF TSE-424 (BAZEDOXIFENE ACETATE) COMPARED TO PLACEBO AND RALOXIFENE IN OSTEOPOROTIC POSTMENOPAUSAL WOMEN
To evaluate the efficacy of bazedoxifene acetate 20 mg and bazedoxifene acetate 40 mg in comparison to placebo in reduction of new vertebral fractures in osteoporotic postmenopausal women after 36 mon...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Wyeth Research Division of Wyeth Pharmaceuticals Inc
Update Il y a 4 ans
A Phase 3, Randomized, Active-controlled, Double-Blind Trial of the Safety, Tolerability and Immunologic Noninferiority of a 13-valent Pneumococcal Conjugate Vaccine Compared to a 7-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given in a 2-, 3-, 4- and 11- to 12-Months Schedule With Routine Pediatric Vaccinations
- To demonstrate that the immune responses to the 7 common pneumococcal conjugates induced by 13vPnC are noninferior to the immune responses induced by 7vPnC when measured 1 month after the infant ser...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Wyeth Research Division of Wyeth Pharmaceuticals Inc
Update Il y a 4 ans
A Double-Blind, Placebo-Controlled, Randomized, Multiple Ascending Dose, Safety Study of MYO-029 Administered to Adult Patients with Becker, Facioscapulohumeral and Limb-Girdle Muscular Dystrophy
Primary objective is to evaluate safety of MYO-029 in adult subjects with muscular dystrophy.
Country
None
organs
None
Specialty
None
unknown
More information
Previous
2
3
4
5
6
7
8
Next